Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
Aditya Bardia(UCLA Health), Allyson J. Ocean(Dana-Farber Cancer Institute), Takefumi Komiya(Parkview Health), Alessandro D. Santin(Yale University), Joshua M. Lang(University of Wisconsin–Madison), Ebenezer A. Kio(Goshen Health), William A. Wegener(Children's Hospital of Philadelphia), Jenny C. Chang(Universität Hamburg), Vincent J. Picozzi(Virginia Mason Medical Center), Jordan Berlin(Dana-Farber Cancer Institute), Trishna Goswami(Gilead Sciences (United States)), Joyce O’Shaughnessy(Baylor University Medical Center), Robert M. Sharkey(Immunomedics (United States)), Kevin Kalinsky(Emory University), Linda T. Vahdat(Dartmouth–Hitchcock Medical Center), Gregory A. Masters(Christiana Care Health System), Pius Maliakal(Dana-Farber Cancer Institute), Wells A. Messersmith(University of Colorado Cancer Center), Q. Hong(Immunomedics (United States)), Alexander Starodub(Dana-Farber Cancer Institute), David M. Goldenberg(Unknown), R Moroose(Orlando Health), Jhanelle E. Gray(Moffitt Cancer Center)
Cited by 371
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
|Cell|2014|2.5k